Jenscare Scientific Co Ltd
HKEX:9877
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Jenscare Scientific Co Ltd
Other Equity
Jenscare Scientific Co Ltd
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
J
|
Jenscare Scientific Co Ltd
HKEX:9877
|
Other Equity
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
APT Medical Inc
SSE:688617
|
Other Equity
¥63.8k
|
CAGR 3-Years
-42%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
J
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
|
Other Equity
¥133.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
80%
|
CAGR 10-Years
N/A
|
|
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
Other Equity
¥303.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Andon Health Co Ltd
SZSE:002432
|
Other Equity
¥1.8B
|
CAGR 3-Years
17%
|
CAGR 5-Years
129%
|
CAGR 10-Years
166%
|
|
|
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
|
Other Equity
-¥14.3m
|
CAGR 3-Years
34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Jenscare Scientific Co Ltd
Glance View
Jenscare Scientific Co., Ltd. is a holding company, which engages in the development and sale of transcatheter aortic valve systems. The company is headquartered in Ningbo, Zhejiang. The company went IPO on 2022-10-10. The firm develops interventional products for the treatment of structural heart disease. The firm's core products include LuX-Valve and Ken-Valve. LuX-Valve is a transcatheter tricuspid valve replacement system designed for patients with severe tricuspid regurgitation and high surgical risk. Ken-Valve is designed for the treatment of severe aortic regurgitation or combined with aortic stenosis. The firm also develops product candidates for the treatment of mitral valve diseases and medical devices for the treatment of heart failure. The firm mainly conducts its businesses in the domestic market.
